Navigation Links
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Date:5/10/2013

NEW YORK, May 10, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo Pharmaceutical, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) securities between January 3, 2012 and May 1, 2013 (the "Class Period").

Aveo is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapies.  The Company's lead product is an oral inhibitor of the vascular endothelial growth factor ("VEGF") receptors.

The Complaint alleges that throughout the Class Period, Defendants conditioned investors to believe that the Company's drug Tivopath (or Tivozanib) would receive approval from the U.S. Food and Drug Administration ("FDA") through a host of materially false and misleading statements regarding its Phase III ("TIVO-1") trial design and results.  Specifically, the Company (a) failed to disclose to investors that the FDA had recommended that the Company conduct an additional Phase III trial due to adverse trends in the Company's first study; (b) misled investors regarding the overall safety and efficacy of the product, including failing to disclose the 25% higher rate of death associated with Tivozanib therapy compared to the control drug, Sorafenib; and (c) failed to disclose that almost 90% of the patients studied in TIVO-1 were enrolled from sites in Central and Eastern Europe with inconsistent treatment patterns from those in the U.S.  As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On April 30, 2013, the FDA released its Oncologic Drugs Advisory Committee ("ODAC")
'/>"/>

SOURCE Bernstein Liebhard LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
2. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
3. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... Los Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... new material has been developed that changes color when subjected to an impact force ... article notes, could be implemented in helmets or other sporting equipment so that coaches ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group ... La Paz. , Schmidt National Law Group, a leading firm in mass-tort litigation, ... against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced ... joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain ... evolving in the consumer goods industry, it can be difficult for companies to ...
(Date:9/4/2015)... ... 2015 , ... “Getting away from the daily stressors and distractions of life ... their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort Maui ... only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... Wash., Feb. 5 The number of Washington retailers illegally ... a new report. The annual rate of illegal sales was ... in 2007 and five percent in 2006. The state ... other state and local agencies to expand the effort to ...
... A Su Salud revealed high incidence of diabetes, osteoporosis, ... million in free and low cost medical services in ... -- CVS/pharmacy, the nation,s leading retail pharmacy, ... (To Your Health) health fairs, providing free health screenings ...
... Researchers from The University of Texas M. D. Anderson ... vessel formation, and vascular endothelial growth factor expression are ... ovarian tumors. This data was presented in a poster ... Annual Meeting on Women,s Cancer. , Sex cord-stromal ...
... Stephens Media LLC of,Las Vegas, Nevada entered ... to deliver Surgery Benefit Management to their health ... care and,personal savings through Healthplace America,s revolutionary surgery ... the Healthplace,Surgery Benefit(TM) is the first -- and ...
... company layoffs, job prospects for rehabilitation therapists ... is projected to increase demand for physical ... assistants up to 27 percent.KENNETT SQUARE, Pa., ... therapy industry continue to experience low rates ...
... Rice University,s Shepherd School of Music will bring together ... in human cognition and behavior for the Exploring the ... the dialogue between musicians and scientists, the conference events ... Shepherd School conference aims to be a trendsetter in ...
Cached Medicine News:Health News:More Retailers Selling Tobacco to Minors 2Health News:More Retailers Selling Tobacco to Minors 3Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Angiogenesis linked to poor survival in patients with rare type of ovarian cancer 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 3Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 4Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 2Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 3Health News:Rice U. conference to explore music's role in human cognition and behavior 2Health News:Rice U. conference to explore music's role in human cognition and behavior 3
... EXOGEN 2000+ device provides a non-invasive ... or the acceleration of fresh fracture ... for 20 minutes daily, or as ... physician determines your fracture to be ...
... growth stimulator is a useful adjunct for the ... or when patient compliance may be a concern. ... are assured of therapeutic treatment directly at the ... to 6 months. , ,The OsteoGen bone growth ...
... Interference Screw has unique, double-helix ... while limiting veering and divergence. ... abrasion where it is most ... thread enables screws to be ...
Cannulated Interference Screws...
Medicine Products: